These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2577 related items for PubMed ID: 17652294

  • 1. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 2. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.
    J Am Coll Cardiol; 2013 Apr 09; 61(14):1527-35. PubMed ID: 23500286
    [Abstract] [Full Text] [Related]

  • 3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun 09; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA, Spirito P.
    N Engl J Med; 2000 Feb 10; 342(6):365-73. PubMed ID: 10666426
    [Abstract] [Full Text] [Related]

  • 5. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 10; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 6. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 10; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 7. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 10; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 8. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 9. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
    Maron BJ, Spirito P.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr 01; 37(4):297-302. PubMed ID: 19791462
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P.
    J Cardiovasc Electrophysiol; 2008 Oct 01; 19(10):1118-26. PubMed ID: 18384577
    [Abstract] [Full Text] [Related]

  • 12. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 01; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.
    Pacing Clin Electrophysiol; 2003 Sep 01; 26(9):1887-96. PubMed ID: 12930505
    [Abstract] [Full Text] [Related]

  • 14. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P, Santini D, Musumeci B, Semprini L, Adduci C, Pagannone E, Proietti G, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2014 Nov 01; 25(11):1180-7. PubMed ID: 25066044
    [Abstract] [Full Text] [Related]

  • 15. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 01; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ, Maron MS.
    Heart Rhythm; 2016 May 01; 13(5):1155-1165. PubMed ID: 26749314
    [Abstract] [Full Text] [Related]

  • 18. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.
    Kardiol Pol; 2012 May 01; 70(12):1264-75. PubMed ID: 23264245
    [Abstract] [Full Text] [Related]

  • 19. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.
    Heart; 2009 May 01; 95(9):709-14. PubMed ID: 19282314
    [Abstract] [Full Text] [Related]

  • 20. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
    Magnusson P, Gadler F, Liv P, Mörner S.
    Pacing Clin Electrophysiol; 2016 Mar 01; 39(3):291-301. PubMed ID: 26681505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 129.